Latest Research Reports on Market Movers Valeant Pharmaceuticals and Chipotle Mexican Grill

NEW YORK, NY / ACCESSWIRE / January 11, 2017 / The Dow Jones Industrial Average dropped slightly Tuesday as the Index was dragged lower by declines from the energy sector. The Dow declined 31.85 points, or 0.16 percent, to close at 19,855.53. Since Election Day, the Index is up roughly 9 percent as investors flocked to shares of financial and industrial companies amidst optimism that a Trump White House would inject life into the U.S. economy with lower corporate taxes and looser financial regulations.

On Tuesday, the Nasdaq Composite Index touched a new intraday record of 5,564.25, before settling to close at 5,551.82, up 3.13 percent year-to-date. The Nasdaq Composite Index has closed the year with a gain 22 out of the 30 times the Index rose in the first 5 trading sessions to begin a new year, according to a Dow Jones markets data group.

Valeant Pharmaceuticals International Inc. (NYSE: VRX)

Get Your Up-To-Date Valeant Pharmaceuticals
Research Report Click Here

Valeant Pharmaceuticals’ shares spiked 6.84 percent to close at $16.40 a share Tuesday. The stock traded between $16.10 and $17.55 on volume of 42.44 million shares traded. On January 10th, the company announced the sale of its CeraVe, AcneFree and AMBI skincare brands to L’Oréal for $1.3 billion in cash. The CeraVe, AcneFree, and AMBI product lines annualized revenues are approximated to be $168 million. Valeant will use the proceeds from the sale to permanently repay term loan debt under its Senior Credit Facility. In another release on January 10th, Valeant also announced results of a second Phase 3 study of its plaque psoriasis treatment lotion, IDP-118.

“Investing in R&D and developing innovative products that improve people’s lives continue to be priorities as we enter 2017,” stated Joseph C. Papa, Chairman and Chief Executive Officer. “We are optimistic about the results of this confirmatory Phase 3 study, which demonstrate that the novel formulation in IDP-118, with its dual mechanism of action, can achieve greater efficacy at a much lower concentration while reducing irritation in patients who use a corticosteroid-retinoid combination to treat psoriasis.”

Chipotle Mexican Grill, Inc. (NYSE: CMG)

Get Your Up-To-Date Chipotle Mexican Grill
Research Report Here

Chipotle Mexican Grill’s shares gained 4.92 percent to close at $414.48 a share Tuesday. The stock traded between $408.20 and $420.23 on volume of 3.21 million shares traded. The company is scheduled to release results for the fourth quarter and full year 2016 on Thursday, February 2nd, 2017 at approximately 4:10 PM Eastern time. Chipotle estimates sales revenue to be $1.035 billion for the fourth quarter of 2016. Chipotle is estimated to report earnings per share of $0.96 and revenues of $1.05 billion for the fourth quarter of 2016, according to consensus by Thomson Reuters I/B/E/S. On January 10th, the company presented at the ICR investor conference in Orlando, Florida.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Hemal K. Gandhi, a CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 452542

Go Top